R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2022-09-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-022-00723-4 |
| _version_ | 1828736488180809728 |
|---|---|
| author | Diana Al-Sarayfi Frederik O. Meeuwes Müjde Durmaz Djamila E. Issa Rolf E. Brouwer Aart Beeker Anna van Rhenen Pim G. N. J. Mutsaers Lara H. Böhmer Marjolein W. M. van der Poel Liane te Boome Tom van Meerten Martine E. D. Chamuleau Josée M. Zijlstra Mirian Brink Marcel Nijland |
| author_facet | Diana Al-Sarayfi Frederik O. Meeuwes Müjde Durmaz Djamila E. Issa Rolf E. Brouwer Aart Beeker Anna van Rhenen Pim G. N. J. Mutsaers Lara H. Böhmer Marjolein W. M. van der Poel Liane te Boome Tom van Meerten Martine E. D. Chamuleau Josée M. Zijlstra Mirian Brink Marcel Nijland |
| author_sort | Diana Al-Sarayfi |
| collection | DOAJ |
| first_indexed | 2024-04-12T23:26:31Z |
| format | Article |
| id | doaj.art-bce0c7d4e1d241edbbcdb1d4287c2136 |
| institution | Directory Open Access Journal |
| issn | 2044-5385 |
| language | English |
| last_indexed | 2024-04-12T23:26:31Z |
| publishDate | 2022-09-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Blood Cancer Journal |
| spelling | doaj.art-bce0c7d4e1d241edbbcdb1d4287c21362022-12-22T03:12:24ZengNature Publishing GroupBlood Cancer Journal2044-53852022-09-011291410.1038/s41408-022-00723-4R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphomaDiana Al-Sarayfi0Frederik O. Meeuwes1Müjde Durmaz2Djamila E. Issa3Rolf E. Brouwer4Aart Beeker5Anna van Rhenen6Pim G. N. J. Mutsaers7Lara H. Böhmer8Marjolein W. M. van der Poel9Liane te Boome10Tom van Meerten11Martine E. D. Chamuleau12Josée M. Zijlstra13Mirian Brink14Marcel Nijland15Department of Hematology, University Medical Center GroningenDepartment of Hematology, Treant HospitalDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL)Department of Internal Medicine, Jeroen Bosch HospitalDepartment of Internal Medicine, Reinier de Graaf GasthuisDepartment of Oncology, Spaarne GasthuisDepartment of Hematology, Cancer Center, UMC UtrechtDepartment of Hematology, Erasmus MC Cancer InstituteDepartment of Hematology, Haga Teaching HospitalDepartment of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical CenterDepartment of Hematology, Haaglanden Medical CenterDepartment of Hematology, University Medical Center GroningenDepartment of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit AmsterdamDepartment of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit AmsterdamDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL)Department of Hematology, University Medical Center Groningenhttps://doi.org/10.1038/s41408-022-00723-4 |
| spellingShingle | Diana Al-Sarayfi Frederik O. Meeuwes Müjde Durmaz Djamila E. Issa Rolf E. Brouwer Aart Beeker Anna van Rhenen Pim G. N. J. Mutsaers Lara H. Böhmer Marjolein W. M. van der Poel Liane te Boome Tom van Meerten Martine E. D. Chamuleau Josée M. Zijlstra Mirian Brink Marcel Nijland R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma Blood Cancer Journal |
| title | R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma |
| title_full | R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma |
| title_fullStr | R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma |
| title_full_unstemmed | R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma |
| title_short | R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma |
| title_sort | r ceop as first line treatment for anthracycline ineligible patients with diffuse large b cell lymphoma |
| url | https://doi.org/10.1038/s41408-022-00723-4 |
| work_keys_str_mv | AT dianaalsarayfi rceopasfirstlinetreatmentforanthracyclineineligiblepatientswithdiffuselargebcelllymphoma AT frederikomeeuwes rceopasfirstlinetreatmentforanthracyclineineligiblepatientswithdiffuselargebcelllymphoma AT mujdedurmaz rceopasfirstlinetreatmentforanthracyclineineligiblepatientswithdiffuselargebcelllymphoma AT djamilaeissa rceopasfirstlinetreatmentforanthracyclineineligiblepatientswithdiffuselargebcelllymphoma AT rolfebrouwer rceopasfirstlinetreatmentforanthracyclineineligiblepatientswithdiffuselargebcelllymphoma AT aartbeeker rceopasfirstlinetreatmentforanthracyclineineligiblepatientswithdiffuselargebcelllymphoma AT annavanrhenen rceopasfirstlinetreatmentforanthracyclineineligiblepatientswithdiffuselargebcelllymphoma AT pimgnjmutsaers rceopasfirstlinetreatmentforanthracyclineineligiblepatientswithdiffuselargebcelllymphoma AT larahbohmer rceopasfirstlinetreatmentforanthracyclineineligiblepatientswithdiffuselargebcelllymphoma AT marjoleinwmvanderpoel rceopasfirstlinetreatmentforanthracyclineineligiblepatientswithdiffuselargebcelllymphoma AT lianeteboome rceopasfirstlinetreatmentforanthracyclineineligiblepatientswithdiffuselargebcelllymphoma AT tomvanmeerten rceopasfirstlinetreatmentforanthracyclineineligiblepatientswithdiffuselargebcelllymphoma AT martineedchamuleau rceopasfirstlinetreatmentforanthracyclineineligiblepatientswithdiffuselargebcelllymphoma AT joseemzijlstra rceopasfirstlinetreatmentforanthracyclineineligiblepatientswithdiffuselargebcelllymphoma AT mirianbrink rceopasfirstlinetreatmentforanthracyclineineligiblepatientswithdiffuselargebcelllymphoma AT marcelnijland rceopasfirstlinetreatmentforanthracyclineineligiblepatientswithdiffuselargebcelllymphoma |